123 related articles for article (PubMed ID: 18772108)
1. Redefining the target again: chemotherapeutics as vascular disrupting agents?
Gokmen-Polar Y; Miller KD
Cancer Cell; 2008 Sep; 14(3):195-6. PubMed ID: 18772108
[TBL] [Abstract][Full Text] [Related]
2. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y; Henke E; Roodhart JM; Mancuso P; Langenberg MH; Colleoni M; Daenen LG; Man S; Xu P; Emmenegger U; Tang T; Zhu Z; Witte L; Strieter RM; Bertolini F; Voest EE; Benezra R; Kerbel RS
Cancer Cell; 2008 Sep; 14(3):263-73. PubMed ID: 18772115
[TBL] [Abstract][Full Text] [Related]
3. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Taylor M; Billiot F; Marty V; Rouffiac V; Cohen P; Tournay E; Opolon P; Louache F; Vassal G; Laplace-Builhé C; Vielh P; Soria JC; Farace F
Cancer Discov; 2012 May; 2(5):434-49. PubMed ID: 22588881
[TBL] [Abstract][Full Text] [Related]
4. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Shaked Y; Tang T; Woloszynek J; Daenen LG; Man S; Xu P; Cai SR; Arbeit JM; Voest EE; Chaplin DJ; Smythe J; Harris A; Nathan P; Judson I; Rustin G; Bertolini F; Link DC; Kerbel RS
Cancer Res; 2009 Oct; 69(19):7524-8. PubMed ID: 19738066
[TBL] [Abstract][Full Text] [Related]
5. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
[TBL] [Abstract][Full Text] [Related]
6. The role of new agents in the treatment of colorectal cancer.
Ruiz de Erenchun F
Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
[No Abstract] [Full Text] [Related]
7. Development and preclinical characterization of a humanized antibody targeting CXCL12.
Zhong C; Wang J; Li B; Xiang H; Ultsch M; Coons M; Wong T; Chiang NY; Clark S; Clark R; Quintana L; Gribling P; Suto E; Barck K; Corpuz R; Yao J; Takkar R; Lee WP; Damico-Beyer LA; Carano RD; Adams C; Kelley RF; Wang W; Ferrara N
Clin Cancer Res; 2013 Aug; 19(16):4433-45. PubMed ID: 23812669
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
9. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis. A boost for tumor starvation.
Marx J
Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
[No Abstract] [Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic profiling identifies novel anticancer drugs.
Cancer Discov; 2011 Dec; 1(7):OF1. PubMed ID: 22586692
[TBL] [Abstract][Full Text] [Related]
13. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
[TBL] [Abstract][Full Text] [Related]
14. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
15. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
16. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic inhibitors: a new therapeutic strategy in oncology.
Gasparini G; Longo R; Toi M; Ferrara N
Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
